LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

2,567
Mkt Cap
$3.62B
Volume
220,974.00
52W High
$212.49
52W Low
$93.58
PE Ratio
88.58
LGND Fundamentals
Price
$183.13
Prev Close
$184.03
Open
$185.93
50D MA
$191.66
Beta
0.98
Avg. Volume
241,882.84
EPS (Annual)
-$0.2204
P/B
3.81
Rev/Employee
$2.46M
Loading...
Loading...
News
all
press releases
Norges Bank Acquires Shares of 14,073 Ligand Pharmaceuticals Incorporated $LGND
Norges Bank bought a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the second quarter, according to the company in its most recent filing with the...
MarketBeat·13h ago
News Placeholder
More News
News Placeholder
Here's How Much $100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Today
read more...
Benzinga·1d ago
News Placeholder
Royal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price
Royal Bank Of Canada boosted their price target on Ligand Pharmaceuticals from $234.00 to $235.00 and gave the stock an "outperform" rating in a report on Wednesday...
MarketBeat·1d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2026 Earnings Guidance
Ligand Pharmaceuticals (NASDAQ:LGND) updated its FY 2026 earnings guidance. The company provided EPS guidance of 8.000-9.000 for the period, compared to the consensus estimate of 6.650. The company...
MarketBeat·2d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Coverage Initiated by Analysts at Citigroup
Citigroup started coverage on shares of Ligand Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $270.00 price target for the company...
MarketBeat·2d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $91,457.28 in Stock
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) Director John Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, December 1st. The...
MarketBeat·7d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) Director John Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, December 1st. The...
MarketBeat·7d ago
News Placeholder
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by Russell Investments Group Ltd.
Russell Investments Group Ltd. grew its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 7.5% in the 2nd quarter, according to the company in its most recent...
MarketBeat·10d ago
News Placeholder
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by Brokerages
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has received an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports...
MarketBeat·10d ago
News Placeholder
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc
Legal & General Group Plc raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 15.8% in the second quarter, according to its most recent Form 13F filing...
MarketBeat·11d ago

Latest LGND News

View

Advertisement|Remove ads.

Advertisement|Remove ads.